Hefei Lifeon Pharmaceutical (SHE:003020) obtained drug registration from China's drug administrator for its methylphenidate hydrochloride extended-release tablets.
The drug is a first-class psychotropic substance mainly used to treat attention deficit hyperactivity disorder, according to a Tuesday filing with the Shenzhen bourse.
Shares of the pharmaceutical company rose 10% in recent trade.